Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors
May 17 2022 - 7:00AM
Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the
“Company”), a clinical-stage biopharmaceutical company focused on
oncology and rare diseases, today announced the appointment of Dr.
Abdul Mullick to the Company’s Board of Directors, effective
immediately. Dr. Mullick joins Mereo’s Board with over 20 years of
experience in the pharmaceutical industry in senior leadership
positions across multiple therapeutic areas and geographies,
including in rare diseases.
“We are very excited to welcome Abdul to the
Board at such a pivotal time for the Company,” said Dr. Denise
Scots-Knight, Chief Executive Officer of Mereo. “His experience in
the rare disease space and leadership while launching two new rare
disease products will be invaluable to Mereo as we continue to
advance our programs through the clinic. I believe Abdul will be an
asset to the Board and very much look forward to working with
him.”
Dr. Mullick currently serves as President &
Chief Executive Officer of Kyowa Kirin International plc (“KKI”), a
subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151) the Japan-based
global specialty pharmaceutical company. During his four years at
KKI, Dr. Mullick successfully led the launch of two new rare
disease products across Europe, the GCC1 and other growth markets,
including for the treatment of X-linked hypophosphatemia, a disease
characterized by low levels of phosphate in the blood. He also led
a drive to enhance patient and customer care, resulting in improved
profitability, as well as accelerating the digital transformation
across the entire value chain. Prior to KKI, Dr. Mullick held
senior positions at Vifor Pharma Ltd. as Head of Global Strategic
Marketing, Novartis as Global Head of the Diabetes Franchise and at
Sanofi where he held roles at the country, regional and global
levels. Most notably, he spent over eight years at Genzyme leading
rare and ultra-rare disease businesses in Europe, Asia (including
China and Japan) and the United States, as well as heading the rare
disease global strategy and marketing function. Dr. Mullick
graduated with a PhD in Molecular Biology from Bristol University
in the UK.
“Mereo has shown outstanding commitment to
helping underserved patient populations and I am honored to be
joining the Board,” added Dr. Mullick. “It is a very exciting time
to be joining Mereo, as the Company has made tremendous strides in
progressing their programs. I have seen first-hand the difference
that innovation in treatments for rare diseases can make,
especially where there are no existing approved therapies. I
believe that Mereo’s late-stage assets have the potential to make a
difference in the lives of patients and look forward to working
with the team.”
_______________1 Gulf Cooperation Council
Markets
About Mereo BioPharmaMereo
BioPharma is a biopharmaceutical company focused on the development
of innovative therapeutics that aim to improve outcomes for
oncology and rare diseases and plans to commercialize selected rare
disease programs. The Company has developed a portfolio of six
clinical stage product candidates. Mereo’s lead oncology product
candidate, etigilimab (anti-TIGIT), has advanced into an open label
Phase 1b/2 basket study evaluating anti-TIGIT in combination with
an anti-PD-1 in a range of tumor types including three rare tumors
and three gynecological carcinomas, cervical, ovarian, and
endometrial carcinomas. The Company’s second oncology product,
navicixizumab, for the treatment of late line ovarian cancer, has
completed a Phase 1 study and has been partnered with OncXerna
Therapeutics, Inc., formerly Oncologie, Inc. The Company has two
rare disease product candidates, alvelestat for the treatment of
severe Alpha-1 antitrypsin deficiency (AATD) and Bronchiolitis
Obliterans Syndrome (BOS), and setrusumab for the treatment of
osteogenesis imperfecta (OI). Alvelestat has received U.S. Orphan
Drug Designation for the treatment of AATD and positive top-line
data were recently reported from a Phase 2 proof-of-concept study
in North America, Europe and the UK. The Company’s partner,
Ultragenyx Pharmaceutical, Inc., has initiated a pivotal Phase 2/3
pediatric study in young adults (5-25 years old) for setrusumab in
OI and expects to initiate a study in pediatric patients (2-5 years
old) in the second half of 2022.
Forward-Looking StatementsThis
press release contains “forward-looking statements.” All statements
other than statements of historical fact contained in this press
release are forward-looking statements within the meaning of
Section 27A of the United States Securities Act of 1933, as amended
(the “Securities Act”), and Section 21E of the United States
Securities Exchange Act of 1934, as amended (the “Exchange Act”).
Forward-looking statements usually relate to future events and
anticipated revenues, earnings, cash flows or other aspects of our
operations or operating results. Forward-looking statements are
often identified by the words “believe,” “expect,” “anticipate,”
“plan,” “intend,” “foresee,” “should,” “would,” “could,” “may,”
“estimate,” “outlook” and similar expressions, including the
negative thereof. The absence of these words, however, does not
mean that the statements are not forward-looking. These
forward-looking statements are based on the Company’s current
expectations, beliefs and assumptions concerning future
developments and business conditions and their potential effect on
the Company. While management believes that these forward-looking
statements are reasonable as and when made, there can be no
assurance that future developments affecting the Company will be
those that it anticipates.
All of the Company’s forward-looking statements
involve known and unknown risks and uncertainties some of which are
significant or beyond its control and assumptions that could cause
actual results to differ materially from the Company’s historical
experience and its present expectations or projections. You should
carefully consider the foregoing factors and the other risks and
uncertainties that affect the Company’s business, including those
described in the “Risk Factors” section of its latest Annual Report
on Form 20-F, reports on Form 6-K and other documents furnished or
filed from time to time by the Company with the Securities and
Exchange Commission. The Company wishes to caution you not to place
undue reliance on any forward-looking statements, which speak only
as of the date hereof. The Company undertakes no obligation to
publicly update or revise any of our forward-looking statements
after the date they are made, whether as a result of new
information, future events or otherwise, except to the extent
required by law.
Mereo BioPharma
Contacts: |
|
|
Mereo |
|
+44 (0)333 023
7300 |
Denise Scots-Knight, Chief
Executive Officer |
|
|
Christine Fox, Chief Financial
Officer |
|
|
|
|
Burns McClellan
(Investor Relations Adviser to Mereo) |
|
+01 212 213
0006 |
Lee Roth |
|
|
Investors |
|
investors@mereobiopharma.com |
|
|
|
Mereo BioPharma (NASDAQ:MREO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mereo BioPharma (NASDAQ:MREO)
Historical Stock Chart
From Sep 2023 to Sep 2024